Tiverton Asset Management LLC Has $336,000 Position in Charles River Laboratories Intl. Inc (NYSE:CRL)

Tiverton Asset Management LLC lessened its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 44.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,369 shares of the medical research company’s stock after selling 1,872 shares during the period. Tiverton Asset Management LLC’s holdings in Charles River Laboratories Intl. were worth $336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Flagship Harbor Advisors LLC increased its stake in shares of Charles River Laboratories Intl. by 132.1% in the second quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after buying an additional 181 shares during the period. Steward Partners Investment Advisory LLC bought a new position in shares of Charles River Laboratories Intl. in the second quarter valued at $69,000. Machina Capital S.A.S. acquired a new position in shares of Charles River Laboratories Intl. during the second quarter valued at about $72,000. Hilton Capital Management LLC acquired a new position in shares of Charles River Laboratories Intl. during the first quarter valued at about $118,000. Finally, Cigna Investments Inc. New bought a new stake in shares of Charles River Laboratories Intl. during the first quarter worth about $201,000. Institutional investors and hedge funds own 94.40% of the company’s stock.

In related news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $130.36, for a total value of $162,819.64. Following the completion of the transaction, the insider now owns 19,327 shares of the company’s stock, valued at approximately $2,519,467.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.80% of the company’s stock.

Several equities analysts recently weighed in on CRL shares. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Svb Leerink started coverage on Charles River Laboratories Intl. in a report on Monday, June 10th. They set an “outperform” rating and a $155.00 price objective for the company. Leerink Swann began coverage on Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating for the company. Finally, Zacks Investment Research cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday. Seven investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Charles River Laboratories Intl. presently has an average rating of “Buy” and an average target price of $147.62.

Shares of Charles River Laboratories Intl. stock traded up $1.35 on Wednesday, hitting $131.03. 6,968 shares of the company traded hands, compared to its average volume of 233,653. Charles River Laboratories Intl. Inc has a 12-month low of $103.00 and a 12-month high of $149.07. The company has a current ratio of 1.59, a quick ratio of 1.38 and a debt-to-equity ratio of 1.47. The company has a market cap of $6.35 billion, a P/E ratio of 21.81, a P/E/G ratio of 1.66 and a beta of 1.09. The firm’s 50-day simple moving average is $132.09 and its 200 day simple moving average is $136.35.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.55 by $0.08. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The business had revenue of $657.60 million for the quarter, compared to the consensus estimate of $662.61 million. During the same quarter last year, the business posted $1.62 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. Analysts predict that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current year.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Can systematic risk be avoided?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.